Novel Tracers and Radionuclides in PET Imaging. Review uri icon

Overview

abstract

  • The use of PET imaging agents in oncology, cardiovascular disease, and neurodegenerative disease shows the power of this technique in evaluating the molecular and biological characteristics of numerous diseases. These agents provide crucial information for designing therapeutic strategies for individual patients. Novel PET tracers are in continual development and many have potential use in clinical and research settings. This article discusses the potential applications of tracers in diagnostics, the biological characteristics of diseases, the ability to provide prognostic indicators, and using this information to guide treatment strategies including monitoring treatment efficacy in real time to improve outcomes and survival.

publication date

  • September 1, 2021

Research

keywords

  • Cardiovascular Diseases
  • Neurodegenerative Diseases
  • Positron-Emission Tomography
  • Precision Medicine
  • Radiopharmaceuticals

Identity

PubMed Central ID

  • PMC9116257

Scopus Document Identifier

  • 85112448983

Digital Object Identifier (DOI)

  • 10.1016/j.rcl.2021.05.012

PubMed ID

  • 34392925

Additional Document Info

volume

  • 59

issue

  • 5